How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "8860"
  ["article_id"]=>
  string(4) "8860"
  [1]=>
  string(88) "Press release Oncology Venture establishes a convertible note program of 100 million SEK"
  ["article_title"]=>
  string(88) "Press release Oncology Venture establishes a convertible note program of 100 million SEK"
  [2]=>
  string(173) "Hørsholm, Denmark (31 March 2020) – Oncology Venture A/S (“OV” or the “Company”) today announced that is has established a convertible note"
  ["short_description"]=>
  string(173) "Hørsholm, Denmark (31 March 2020) – Oncology Venture A/S (“OV” or the “Company”) today announced that is has established a convertible note"
  [3]=>
  string(335) "
Hørsholm, Denmark (31 March 2020) – Oncology Venture A/S (“OV” or the “Company”) today announced that is has established a convertible note program of 100 Million SEK. The issuance of the convertible bonds is in the full control of Oncology Venture.
"
  ["description"]=>
  string(335) "
Hørsholm, Denmark (31 March 2020) – Oncology Venture A/S (“OV” or the “Company”) today announced that is has established a convertible note program of 100 Million SEK. The issuance of the convertible bonds is in the full control of Oncology Venture.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(159) "http://www.globenewswire.com/news-release/2020/03/31/2009137/0/en/Press-release-Oncology-Venture-establishes-a-convertible-note-program-of-100-million-SEK.html"
  ["blog_url"]=>
  string(159) "http://www.globenewswire.com/news-release/2020/03/31/2009137/0/en/Press-release-Oncology-Venture-establishes-a-convertible-note-program-of-100-million-SEK.html"
  [15]=>
  string(19) "2020-03-31 20:30:00"
  ["add_date"]=>
  string(19) "2020-03-31 20:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:41:59"
  ["create_at"]=>
  string(19) "2020-04-12 16:41:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Press release Oncology Venture establishes a convertible note program of 100 million SEK

Hørsholm, Denmark (31 March 2020) – Oncology Venture A/S (“OV” 

array(40) {
  [0]=>
  string(4) "8930"
  ["article_id"]=>
  string(4) "8930"
  [1]=>
  string(76) "Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus"
  ["article_title"]=>
  string(76) "Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus"
  [2]=>
  string(155) "Johnson & Johnson’s global head of external innovation says there needs to be a shift in how healthcare research is funded to focus on early det"
  ["short_description"]=>
  string(155) "Johnson & Johnson’s global head of external innovation says there needs to be a shift in how healthcare research is funded to focus on early det"
  [3]=>
  string(377) "Johnson & Johnson’s global head of external innovation says there needs to be a shift in how healthcare research is funded to focus on early detection and curing rather than managing diseases. “When you look at the investment in research in the pharma industry, it’s all designed to treat established diseases,” William Hait, global head […]"
  ["description"]=>
  string(377) "Johnson & Johnson’s global head of external innovation says there needs to be a shift in how healthcare research is funded to focus on early detection and curing rather than managing diseases. “When you look at the investment in research in the pharma industry, it’s all designed to treat established diseases,” William Hait, global head […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "37"
  ["rss_id"]=>
  string(2) "37"
  [14]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/TCF4yFDo2iU/"
  ["blog_url"]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/TCF4yFDo2iU/"
  [15]=>
  string(19) "2020-03-31 19:00:12"
  ["add_date"]=>
  string(19) "2020-03-31 19:00:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:12"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:12"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus

Johnson & Johnson’s global head of external innovation says there needs to be a shift in how healthcare resea

array(40) {
  [0]=>
  string(4) "8963"
  ["article_id"]=>
  string(4) "8963"
  [1]=>
  string(62) "Medical Plastics News Europe - Issue 52, January-February 2020"
  ["article_title"]=>
  string(62) "Medical Plastics News Europe - Issue 52, January-February 2020"
  [2]=>
  string(96) "You can view all of the articles from this issue individually in full here.
&#nl
&#nl"
  ["short_description"]=>
  string(96) "You can view all of the articles from this issue individually in full here.
&#nl
&#nl"
  [3]=>
  string(171) "You can view all of the articles from this issue individually in full here.
&#nl
&#nl"
  ["description"]=>
  string(171) "You can view all of the articles from this issue individually in full here.
&#nl
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(96) "https://www.medicalplasticsnews.com/medical-plastics-news-europe-issue-52-january-february-2020/"
  ["blog_url"]=>
  string(96) "https://www.medicalplasticsnews.com/medical-plastics-news-europe-issue-52-january-february-2020/"
  [15]=>
  string(19) "2020-03-31 18:36:50"
  ["add_date"]=>
  string(19) "2020-03-31 18:36:50"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Medical Plastics News Europe - Issue 52, January-February 2020

You can view all of the articles from this issue individually in full  

array(40) {
  [0]=>
  string(4) "8964"
  ["article_id"]=>
  string(4) "8964"
  [1]=>
  string(87) "Healthtech company hopes patent will enable a 'digital and connected community'"
  ["article_title"]=>
  string(87) "Healthtech company hopes patent will enable a 'digital and connected community'"
  [2]=>
  string(150) "Swedish healthtech company Brighter, has been granted a patent for computer driven supervision of the health of portable medical devices in Indonesia."
  ["short_description"]=>
  string(150) "Swedish healthtech company Brighter, has been granted a patent for computer driven supervision of the health of portable medical devices in Indonesia."
  [3]=>
  string(150) "Swedish healthtech company Brighter, has been granted a patent for computer driven supervision of the health of portable medical devices in Indonesia."
  ["description"]=>
  string(150) "Swedish healthtech company Brighter, has been granted a patent for computer driven supervision of the health of portable medical devices in Indonesia."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(101) "https://www.medicalplasticsnews.com/news/healthtech-company-receives-patent-for-ai-powered-safety-mo/"
  ["blog_url"]=>
  string(101) "https://www.medicalplasticsnews.com/news/healthtech-company-receives-patent-for-ai-powered-safety-mo/"
  [15]=>
  string(19) "2020-03-31 18:14:07"
  ["add_date"]=>
  string(19) "2020-03-31 18:14:07"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Healthtech company hopes patent will enable a 'digital and connected community'

Swedish healthtech company Brighter, has been granted a patent for computer driven supervision of the health of portable

array(40) {
  [0]=>
  string(4) "8997"
  ["article_id"]=>
  string(4) "8997"
  [1]=>
  string(71) "Employers adopt new tech to help reduce impact of Covid-19 on workforce"
  ["article_title"]=>
  string(71) "Employers adopt new tech to help reduce impact of Covid-19 on workforce"
  [2]=>
  string(150) "e-days provides businesses with data on employee self-isolation and illness System signposts virtual GP appointments, relieving pressure on NHS during"
  ["short_description"]=>
  string(150) "e-days provides businesses with data on employee self-isolation and illness System signposts virtual GP appointments, relieving pressure on NHS during"
  [3]=>
  string(531) "e-days provides businesses with data on employee self-isolation and illness System signposts virtual GP appointments, relieving pressure on NHS during lockdown Knowing which colleagues have displayed symptoms could be critical to the wider workforce London, UK: 31st March 2020: New HR tech has been released in response to COVID-19 to help employers maintain staff wellbeing and ensure they get the most appropriate medical help available if affected by the virus. e-days, the absence management company...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(531) "e-days provides businesses with data on employee self-isolation and illness System signposts virtual GP appointments, relieving pressure on NHS during lockdown Knowing which colleagues have displayed symptoms could be critical to the wider workforce London, UK: 31st March 2020: New HR tech has been released in response to COVID-19 to help employers maintain staff wellbeing and ensure they get the most appropriate medical help available if affected by the virus. e-days, the absence management company...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(105) "https://www.realwire.com/releases/Employers-adopt-new-tech-to-help-reduce-impact-of-Covid-19-on-workforce"
  ["blog_url"]=>
  string(105) "https://www.realwire.com/releases/Employers-adopt-new-tech-to-help-reduce-impact-of-Covid-19-on-workforce"
  [15]=>
  string(19) "2020-03-31 17:00:00"
  ["add_date"]=>
  string(19) "2020-03-31 17:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:35"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Employers adopt new tech to help reduce impact of Covid-19 on workforce

e-days provides businesses with data on employee self-isolation and illness System signposts virtual GP appointments, re

array(40) {
  [0]=>
  string(4) "8502"
  ["article_id"]=>
  string(4) "8502"
  [1]=>
  string(33) "Monthly News Roundup - March 2020"
  ["article_title"]=>
  string(33) "Monthly News Roundup - March 2020"
  [2]=>
  string(153) "Sarclisa Approved to Treat Patients with Advancing Multiple Myeloma&#nlMultiple myeloma is an incurable blood cancer that forms in the bone marrow. This "
  ["short_description"]=>
  string(153) "Sarclisa Approved to Treat Patients with Advancing Multiple Myeloma&#nlMultiple myeloma is an incurable blood cancer that forms in the bone marrow. This "
  [3]=>
  string(239) "Sarclisa Approved to Treat Patients with Advancing Multiple Myeloma&#nlMultiple myeloma is an incurable blood cancer that forms in the bone marrow. This month, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Sarclisa..."
  ["description"]=>
  string(239) "Sarclisa Approved to Treat Patients with Advancing Multiple Myeloma&#nlMultiple myeloma is an incurable blood cancer that forms in the bone marrow. This month, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Sarclisa..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(146) "https://www.drugs.com/news/monthly-news-roundup-march-2020-89287.html?utm_source=ddc&utm_medium=rss&utm_campaign=Monthly+News+Roundup+-+March+2020"
  ["blog_url"]=>
  string(146) "https://www.drugs.com/news/monthly-news-roundup-march-2020-89287.html?utm_source=ddc&utm_medium=rss&utm_campaign=Monthly+News+Roundup+-+March+2020"
  [15]=>
  string(19) "2020-03-31 10:03:01"
  ["add_date"]=>
  string(19) "2020-03-31 10:03:01"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:17:59"
  ["create_at"]=>
  string(19) "2020-03-31 11:17:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Monthly News Roundup - March 2020

Sarclisa Approved to Treat Patients with Advancing Multiple Myeloma&#nlMultiple myeloma is an incurable blood cancer tha

array(40) {
  [0]=>
  string(4) "8610"
  ["article_id"]=>
  string(4) "8610"
  [1]=>
  string(296) "Johnson & Johnson anuncia una vacuna experimental inicial para la COVID-19, una nueva colaboración histórica con el Departamento de Salud y Servicios Humanos de los EE. UU. y su compromiso para suministrar mil millones de vacunas en todo el mundo para uso de emergencia ante la pandemia"
  ["article_title"]=>
  string(296) "Johnson & Johnson anuncia una vacuna experimental inicial para la COVID-19, una nueva colaboración histórica con el Departamento de Salud y Servicios Humanos de los EE. UU. y su compromiso para suministrar mil millones de vacunas en todo el mundo para uso de emergencia ante la pandemia"
  [2]=>
  string(154) "NEW BRUNSWICK, Nueva Jersey, 30 de marzo de 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (la empresa) anunció hoy la selección de una vacuna e"
  ["short_description"]=>
  string(154) "NEW BRUNSWICK, Nueva Jersey, 30 de marzo de 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (la empresa) anunció hoy la selección de una vacuna e"
  [3]=>
  string(306) "
NEW BRUNSWICK, Nueva Jersey, 30 de marzo de 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (la empresa) anunció hoy la selección de una vacuna experimental inicial contra la COVID-19 a partir de preparados en los que trabaja desde enero de 2020; la importante expansión de la alianza...
"
  ["description"]=>
  string(306) "
NEW BRUNSWICK, Nueva Jersey, 30 de marzo de 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (la empresa) anunció hoy la selección de una vacuna experimental inicial contra la COVID-19 a partir de preparados en los que trabaja desde enero de 2020; la importante expansión de la alianza...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(300) "https://www.prnewswire.com:443/news-releases/johnson-amp-johnson-anuncia-una-vacuna-experimental-inicial-para-la-covid-19-una-nueva-colaboracion-historica-con-el-departamento-de-salud-y-servicios-humanos-de-los-ee-uu-y-su-compromiso-para-suministrar-mil-millones-de-vacunas-en-todo-el--839306805.html"
  ["blog_url"]=>
  string(300) "https://www.prnewswire.com:443/news-releases/johnson-amp-johnson-anuncia-una-vacuna-experimental-inicial-para-la-covid-19-una-nueva-colaboracion-historica-con-el-departamento-de-salud-y-servicios-humanos-de-los-ee-uu-y-su-compromiso-para-suministrar-mil-millones-de-vacunas-en-todo-el--839306805.html"
  [15]=>
  string(19) "2020-03-31 09:56:00"
  ["add_date"]=>
  string(19) "2020-03-31 09:56:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:24"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Johnson & Johnson anuncia una vacuna experimental inicial para la COVID-19, una nueva

NEW BRUNSWICK, Nueva Jersey, 30 de marzo de 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (la empresa) anunciÃ

array(40) {
  [0]=>
  string(4) "8611"
  ["article_id"]=>
  string(4) "8611"
  [1]=>
  string(227) "GHIT Fund Announces New Investments: A Total of 3.29 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease, Lymphatic Filariasis, and Onchocerciasis, Vaccines for Malaria, and Diagnostics for Leishmaniasis and Mycetoma"
  ["article_title"]=>
  string(227) "GHIT Fund Announces New Investments: A Total of 3.29 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease, Lymphatic Filariasis, and Onchocerciasis, Vaccines for Malaria, and Diagnostics for Leishmaniasis and Mycetoma"
  [2]=>
  string(150) "TOKYO, March 30, 2020 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of 3.29 billion yen (US$30 million*)"
  ["short_description"]=>
  string(150) "TOKYO, March 30, 2020 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of 3.29 billion yen (US$30 million*)"
  [3]=>
  string(290) "
TOKYO, March 30, 2020 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of 3.29 billion yen (US$30 million*) to invest in 11 partnerships to develop new lifesaving drugs, vaccines and diagnostics for malaria, tuberculosis, Chagas disease,...
"
  ["description"]=>
  string(290) "
TOKYO, March 30, 2020 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of 3.29 billion yen (US$30 million*) to invest in 11 partnerships to develop new lifesaving drugs, vaccines and diagnostics for malaria, tuberculosis, Chagas disease,...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(280) "https://www.prnewswire.com:443/news-releases/ghit-fund-announces-new-investments-a-total-of-3-29-billion-yen-in-drugs-for-malaria-tuberculosis-chagas-disease-lymphatic-filariasis-and-onchocerciasis-vaccines-for-malaria-and-diagnostics-for-leishmaniasis-and-mycetoma-301032122.html"
  ["blog_url"]=>
  string(280) "https://www.prnewswire.com:443/news-releases/ghit-fund-announces-new-investments-a-total-of-3-29-billion-yen-in-drugs-for-malaria-tuberculosis-chagas-disease-lymphatic-filariasis-and-onchocerciasis-vaccines-for-malaria-and-diagnostics-for-leishmaniasis-and-mycetoma-301032122.html"
  [15]=>
  string(19) "2020-03-31 09:00:00"
  ["add_date"]=>
  string(19) "2020-03-31 09:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:24"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

GHIT Fund Announces New Investments: A Total of 3.29 Billion Yen in Drugs for Malaria, Tub

TOKYO, March 30, 2020 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of 

array(40) {
  [0]=>
  string(4) "8612"
  ["article_id"]=>
  string(4) "8612"
  [1]=>
  string(146) "Via anuncia ronda de financiamiento Serie E para ampliar el acceso a una movilidad pública eficiente, sustentable y equitativa en todo el mundo"
  ["article_title"]=>
  string(146) "Via anuncia ronda de financiamiento Serie E para ampliar el acceso a una movilidad pública eficiente, sustentable y equitativa en todo el mundo"
  [2]=>
  string(154) "John Elkann, presidente y director general de EXOR, es el principal inversionista de la ronda de financiamiento: "Nunca ha sido tan importante trabaja"
  ["short_description"]=>
  string(154) "John Elkann, presidente y director general de EXOR, es el principal inversionista de la ronda de financiamiento: "Nunca ha sido tan importante trabaja"
  [3]=>
  string(312) "
John Elkann, presidente y director general de EXOR, es el principal inversionista de la ronda de financiamiento: "Nunca ha sido tan importante trabajar por un futuro innovador y sustentable". NUEVA YORK, 31 de marzo de 2020 /PRNewswire/ -- Via, la compañía que proporciona infraestructura...
"
  ["description"]=>
  string(312) "
John Elkann, presidente y director general de EXOR, es el principal inversionista de la ronda de financiamiento: "Nunca ha sido tan importante trabajar por un futuro innovador y sustentable". NUEVA YORK, 31 de marzo de 2020 /PRNewswire/ -- Via, la compañía que proporciona infraestructura...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(202) "https://www.prnewswire.com:443/news-releases/via-anuncia-ronda-de-financiamiento-serie-e-para-ampliar-el-acceso-a-una-movilidad-publica-eficiente-sustentable-y-equitativa-en-todo-el-mundo-809366851.html"
  ["blog_url"]=>
  string(202) "https://www.prnewswire.com:443/news-releases/via-anuncia-ronda-de-financiamiento-serie-e-para-ampliar-el-acceso-a-una-movilidad-publica-eficiente-sustentable-y-equitativa-en-todo-el-mundo-809366851.html"
  [15]=>
  string(19) "2020-03-31 08:21:00"
  ["add_date"]=>
  string(19) "2020-03-31 08:21:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:24"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Via anuncia ronda de financiamiento Serie E para ampliar el acceso a una movilidad públ

John Elkann, presidente y director general de EXOR, es el principal inversionista de la ronda de financiamiento: "

array(40) {
  [0]=>
  string(4) "8613"
  ["article_id"]=>
  string(4) "8613"
  [1]=>
  string(89) "Khiron Meets Essential Patient Needs with Launch of Teleconsultation Services in Colombia"
  ["article_title"]=>
  string(89) "Khiron Meets Essential Patient Needs with Launch of Teleconsultation Services in Colombia"
  [2]=>
  string(154) "Starting April 1st, Company's virtual consultation service gives patients access to clinic services and doctors trained to prescribe medical cannabis "
  ["short_description"]=>
  string(154) "Starting April 1st, Company's virtual consultation service gives patients access to clinic services and doctors trained to prescribe medical cannabis "
  [3]=>
  string(300) "
Starting April 1st, Company's virtual consultation service gives patients access to clinic services and doctors trained to prescribe medical cannabis Teleconsultation service anticipated to quickly expand to meet potential growing demand for telehealth services, including Company's...
"
  ["description"]=>
  string(300) "
Starting April 1st, Company's virtual consultation service gives patients access to clinic services and doctors trained to prescribe medical cannabis Teleconsultation service anticipated to quickly expand to meet potential growing demand for telehealth services, including Company's...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(149) "https://www.prnewswire.com:443/news-releases/khiron-meets-essential-patient-needs-with-launch-of-teleconsultation-services-in-colombia-301032138.html"
  ["blog_url"]=>
  string(149) "https://www.prnewswire.com:443/news-releases/khiron-meets-essential-patient-needs-with-launch-of-teleconsultation-services-in-colombia-301032138.html"
  [15]=>
  string(19) "2020-03-31 08:21:00"
  ["add_date"]=>
  string(19) "2020-03-31 08:21:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:24"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Khiron Meets Essential Patient Needs with Launch of Teleconsultation Services in Colombia

Starting April 1st, Company's virtual consultation service gives patients access to clinic services and doctors t

array(40) {
  [0]=>
  string(4) "8614"
  ["article_id"]=>
  string(4) "8614"
  [1]=>
  string(131) "TriNet Webinar: Bridging the Health Coverage Gap--Facilitating Access to Alternative Offerings for Small and Medium Size Businesses"
  ["article_title"]=>
  string(131) "TriNet Webinar: Bridging the Health Coverage Gap--Facilitating Access to Alternative Offerings for Small and Medium Size Businesses"
  [2]=>
  string(150) "DUBLIN, Calif., March 30, 2020 /PRNewswire/ -- WHAT: Webinar: Bridging the Health Coverage Gap With COVID-19 delivering the U.S. economy a hard hit, a"
  ["short_description"]=>
  string(150) "DUBLIN, Calif., March 30, 2020 /PRNewswire/ -- WHAT: Webinar: Bridging the Health Coverage Gap With COVID-19 delivering the U.S. economy a hard hit, a"
  [3]=>
  string(292) "
DUBLIN, Calif., March 30, 2020 /PRNewswire/ -- WHAT: Webinar: Bridging the Health Coverage Gap With COVID-19 delivering the U.S. economy a hard hit, along with employees at risk of losing their health coverage, small and medium size businesses need to understand the range of health...
"
  ["description"]=>
  string(292) "
DUBLIN, Calif., March 30, 2020 /PRNewswire/ -- WHAT: Webinar: Bridging the Health Coverage Gap With COVID-19 delivering the U.S. economy a hard hit, along with employees at risk of losing their health coverage, small and medium size businesses need to understand the range of health...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(188) "https://www.prnewswire.com:443/news-releases/trinet-webinar-bridging-the-health-coverage-gapfacilitating-access-to-alternative-offerings-for-small-and-medium-size-businesses-301032128.html"
  ["blog_url"]=>
  string(188) "https://www.prnewswire.com:443/news-releases/trinet-webinar-bridging-the-health-coverage-gapfacilitating-access-to-alternative-offerings-for-small-and-medium-size-businesses-301032128.html"
  [15]=>
  string(19) "2020-03-31 07:59:00"
  ["add_date"]=>
  string(19) "2020-03-31 07:59:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:24"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

TriNet Webinar: Bridging the Health Coverage Gap--Facilitating Access to Alternative Offer

DUBLIN, Calif., March 30, 2020 /PRNewswire/ -- WHAT: Webinar: Bridging the Health Coverage Gap With COVID-19 deliveri

array(40) {
  [0]=>
  string(4) "8580"
  ["article_id"]=>
  string(4) "8580"
  [1]=>
  string(69) "FDA Adds Questions and Answers to Coronavirus Clinical Trial Guidance"
  ["article_title"]=>
  string(69) "FDA Adds Questions and Answers to Coronavirus Clinical Trial Guidance"
  [2]=>
  string(153) "&#nl        The FDA has updated its guidance on conducting clinical trials during the COVID-19 pandemic with an extensive Q&A section, including a long l"
  ["short_description"]=>
  string(153) "&#nl        The FDA has updated its guidance on conducting clinical trials during the COVID-19 pandemic with an extensive Q&A section, including a long l"
  [3]=>
  string(263) "&#nl        The FDA has updated its guidance on conducting clinical trials during the COVID-19 pandemic with an extensive Q&A section, including a long list of factors to consider when deciding the status of ongoing trials and ones soon to be initiated.&#nl      "
  ["description"]=>
  string(263) "&#nl        The FDA has updated its guidance on conducting clinical trials during the COVID-19 pandemic with an extensive Q&A section, including a long list of factors to consider when deciding the status of ongoing trials and ones soon to be initiated.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(109) "https://www.fdanews.com/articles/196449-fda-adds-questions-and-answers-to-coronavirus-clinical-trial-guidance"
  ["blog_url"]=>
  string(109) "https://www.fdanews.com/articles/196449-fda-adds-questions-and-answers-to-coronavirus-clinical-trial-guidance"
  [15]=>
  string(19) "2020-03-31 07:12:05"
  ["add_date"]=>
  string(19) "2020-03-31 07:12:05"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:06"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Adds Questions and Answers to Coronavirus Clinical Trial Guidance

&#nl The FDA has updated its guidance on conducting clinical trials during the COVID-19 pandemic with an extensiv